Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SARS-CoV-2 positive Real Time - Polymerase Chain Reaction~* Moderate to severe Acute respiratory distress syndrome according to Murray classification.~* PaO2/FiO2 less than 200 mmHg.~* Within 36 hours of orotracheal intubation.~* Absence of response with previous standard therapy.~* Willing to participate in the study expressed by patient or responsible caregiver.~* Not being in other clinical trial.~Exclusion Criteria:~* Current pregnancy.~* Cardiac rhythm abnormalities with instability.~* Acute congestive heart failure/cardiogenic shock.~* Severe comorbidities affecting mortality as defined by research group.~* Cancer history in the past 5 years.~* HIV, syphilis, hepatitis B or C.~* Concomitant use of immunosuppressive therapy with contraindication to MSC.~* Fivefold elevation of liver enzymes (ALT, AST).~* Chronic kidney disease with glomerular filtration rate below 30ml/min or dialytic needs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Mesenchymal stem cell (Type: EXPERIMENTAL): WJ MSC 50\*10e6, two doses plus standard treatment with hydroxychloroquine + Lopinavir/Ritonavir or Azithromycin and ventilation support.
- Control group (Type: ACTIVE_COMPARATOR): Hydroxychloroquine, lopinavir/ritonavir and ventilation support plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).